@article {69, title = {Anti-hyperglycemic and Anti-lipidemic activities of Diabac (a polyherbal formulation) in Streptozotocin-nicotinamide induced type 2 diabetic rats}, journal = {Pharmacognosy Journal}, volume = {7}, year = {2015}, month = {01/2015}, pages = {283-288}, type = {Original Article}, chapter = {283}, abstract = {

Aim: The objective of the work was to investigate the antidiabetic activity of Diabac (a polyherbal formulation) in streptozotocin-nicotinamide induced type 2 diabetic rats. Methods: Oral glucose tolerance test (OGTT) was performed to evaluate effect of Diabac on elevated glucose level. The type 2 diabetes was induced by overnight fasted rats by a single intraperitoneal (i.p.) injection of 65 mg/kg streptozotocin, 15 min. after the i.p. administration of 110 mg/kg nicotinamide. The diabetic rats were treated with Diabac (250, 500 and 1000 mg/kg, p.o.) or glibenclamide (5 mg/kg, p.o) for four week. Various parameters were studied such as fasting blood sugar level, serum insulin levels, glycated hemoglobin (HbA1C), serum lipid levels, se rum creatinine, urea, uric acid and liver glycogen. Results: Treatment with Diabac significantly reduced the blood sugar levels in OGTT. Diabetic rats showed a significant increase in the levels of glycated hemoglobin, serum lipids, serum creatinine, urea and uric acid, whereas there was a decrease in serum insulin, liver glycogen and HDL-C levels as compared to normal control rats. The administration of Diabac or glibenclamide significantly decreased the levels of glycated hemoglobin, TG, TC, LDL-C, serum creatinine, urea and uric acid, whereas there was an increase in the levels of liver glycogen and HDL-C as compared to diabetic control rats. However, the treatment with Diabac did not show any significant change in serum insulin levels as compared to diabetic control rats. Conclusion: These results of present study concluded that Diabac has anti-diabetic and anti-lipidemic activities which are responsible for its use in traditional medicine.

}, keywords = {Diabac, Glycated hemoglobin, Liver glycogen, Serum lipids, Streptozotocin.}, doi = {10.5530/pj.2015.5.6}, author = {Richa Agrawal and Rajesh Maheshwari and Ramachandran Balaraman and Avinash Seth} } @article {78, title = {Hepatoprotective effect of Livplus-A polyherbal formulation}, journal = {Pharmacognosy Journal}, volume = {7}, year = {2015}, month = {01/2015}, pages = {311-316}, type = {Original Article}, chapter = {311}, abstract = {

Objective: The aim of the present study was to investigate the hepatoprotective effect of Livplus (a polyherbal formulation) against CCl4-induced hepatotoxicity in rats. Methods: Hepatotoxicity was induced in rats by i.p. injection of CCl4 once three days for 14 days. Livplus or Silymarin was administered along with CCl4 and the biochemical parameters like aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkalinephosphatase (ALP), total bilirubin (TB), direct bilirubin, total protein (TP), gamma-glutamyl transferase (GGT), total cholesterol (TC) and triglycerides (TG) were estimated. Furthermore, biomarkers of oxidative stress such as MDA levels, Glutathione contents, SOD and catalase activity in liver tissue were estimated. Results: Treatment with Livplus significantly reduced the elevated levels of ALT, AST, ALP, bilirubin (direct and total), GGT, TC, TG and increased levels of TP compared to CCl4 control rats. The treatment with Livplus also showed a significant increase in glutathione contents, SOD and catalase activity and a decrease in MDA levels compared to CCl4 control rats. Conclusion: The finding of present study indicates that Livplus showed a potential hepatoprotective activity. These results support the traditional use of Livplus in the treatment of liver disorders.

}, keywords = {CCl4, GGT, Hepatic enzymes., Hepatotoxicity, Livplus}, doi = {10.5530/pj.2015.5.11}, author = {Rajesh Maheshwari and Bhagyashree Pandya and Ramachandran Balaraman and Avinash Kumar Seth and Yogesh Chand Yadav and Vasa Siva Sankar} }